CITI GOOD CLINICAL PRACTICE COURSE
(US FDA FOCUS ) EXAM WITH CORRECT
ACTUAL QUESTIONS AND CORRECTLY
WELL DEFINED ANSWERS LATEST
ALREADY GRADED A+ 2025 - 2026
The sponsor must submit an IND Safety Report to the FDA if an
adverse event is (1) serious; (2) unexpected; and: - ANSWERS-(3)
there is a reasonable possibility that the drug caused the event.
A double-blinded trial for a new indication is conducted under an
IND comparing two (2) marketed drugs, at twice the approved
prescribed doses. On Day 2, subject 603 had difficulty breathing.
Although it was life-threatening initially, subject 603 was treated
and discharged directly from the emergency department after
complete recovery. On Day 5, subject 20 had a headache, which led
to hospitalization and required blood pressure lowering
, medications. These episodes cannot be explained on the basis of
the pharmacological property of either drug or the subjects'
medical histories. The investigator would submit an SAE report for: -
ANSWERS-Both of the subjects
During the course of administration of an investigational drug, the
following events occurred: On Day 7, subject 603 had an
unexpected stroke that requires hospitalization; On Day 15, subject
415 complained of nausea, vomiting, and headache relieved by
aspirin; On Day 21, subject 20 has brief dizzy spells upon trying to
stand. Which of these subject's events meets the FDA definition of
"serious" and "unexpected" and would require the sponsor to file
an IND Safety Report with the FDA? - ANSWERS-Subject 603 only
Subject 311 has had elevated white blood cell (WBC) counts for the
past two (2) study visits, with no clinical signs or symptoms.
"Increased WBC count" is not listed in the Investigator's Brochure
(IB) as an adverse event. The investigator should: - ANSWERS-
Report the elevated WBC to the sponsor as an unexpected adverse
event
Adults with more than a twelve (12)-month history of migraines
were assigned randomly in a double-blinded study to receive
treatment with experimental drug X (10 or 20 mg/day) or placebo.
The primary efficacy measure was the reduction in severity of the
migraine attacks. Enrollment was twelve-hundred (1200) subjects.
(US FDA FOCUS ) EXAM WITH CORRECT
ACTUAL QUESTIONS AND CORRECTLY
WELL DEFINED ANSWERS LATEST
ALREADY GRADED A+ 2025 - 2026
The sponsor must submit an IND Safety Report to the FDA if an
adverse event is (1) serious; (2) unexpected; and: - ANSWERS-(3)
there is a reasonable possibility that the drug caused the event.
A double-blinded trial for a new indication is conducted under an
IND comparing two (2) marketed drugs, at twice the approved
prescribed doses. On Day 2, subject 603 had difficulty breathing.
Although it was life-threatening initially, subject 603 was treated
and discharged directly from the emergency department after
complete recovery. On Day 5, subject 20 had a headache, which led
to hospitalization and required blood pressure lowering
, medications. These episodes cannot be explained on the basis of
the pharmacological property of either drug or the subjects'
medical histories. The investigator would submit an SAE report for: -
ANSWERS-Both of the subjects
During the course of administration of an investigational drug, the
following events occurred: On Day 7, subject 603 had an
unexpected stroke that requires hospitalization; On Day 15, subject
415 complained of nausea, vomiting, and headache relieved by
aspirin; On Day 21, subject 20 has brief dizzy spells upon trying to
stand. Which of these subject's events meets the FDA definition of
"serious" and "unexpected" and would require the sponsor to file
an IND Safety Report with the FDA? - ANSWERS-Subject 603 only
Subject 311 has had elevated white blood cell (WBC) counts for the
past two (2) study visits, with no clinical signs or symptoms.
"Increased WBC count" is not listed in the Investigator's Brochure
(IB) as an adverse event. The investigator should: - ANSWERS-
Report the elevated WBC to the sponsor as an unexpected adverse
event
Adults with more than a twelve (12)-month history of migraines
were assigned randomly in a double-blinded study to receive
treatment with experimental drug X (10 or 20 mg/day) or placebo.
The primary efficacy measure was the reduction in severity of the
migraine attacks. Enrollment was twelve-hundred (1200) subjects.
